CRISPR Therapeutics AG (CRSP) EBITDA Margin Growth (3y) (2019 - 2026)

CRISPR Therapeutics AG (CRSP) EBITDA Margin Growth (3y) (2019 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -377.00
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn -204.00
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 828,504.00
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 7,261.00
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -7.76 Bn
7 Royalty Pharma 33.72 Bn 35.84 Bn - -2,649.00
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 9,003.00
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 30,461.00
10 CRISPR Therapeutics AG 5.18 Bn 5.18 Bn - -101,581.00

Historic Data

Download Data
DateValue
Jun 30, 2026 -101,581.00
Mar 31, 2026 -886,885.00
Dec 31, 2025 217.44 Mn
Sep 30, 2025 17.92 Mn
Jun 30, 2025 9.03 Mn
Mar 31, 2025 156,158.00
Dec 31, 2024 94,857.00
Sep 30, 2024 -265,701.00
Jun 30, 2024 -2.93 Mn
Mar 31, 2024 -664,323.00
Dec 31, 2023 2.92 Mn
Jun 30, 2023 18.32 Mn
Mar 31, 2023 4.68 Mn
Dec 31, 2022 -219.24 Mn
Sep 30, 2022 -19.41 Mn
Jun 30, 2022 -9.87 Mn
Mar 31, 2022 -395,732.00
Dec 31, 2021 3.82 Mn
Sep 30, 2021 -685,691.00
Jun 30, 2021 351,169.00